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 Impaired insulin signalling is seen in the brain of those with Alzheimer’s Disease. 
 A literature review was performed to assess the effect of insulin sensitizers. 
 Improvements in cognition, Amyloid  and tau pathology were demonstrated in mice. 














Alzheimer’s Disease (AD) presents as a gradual decline in cognitive function, with its 
characteristic pathology consisting of Amyloid  (A) accumulation and hyperphosphorylated 
tau. Impaired insulin signalling was recently found in the brain in AD, and shown to increase 
AD pathology. Similar insulin resistance is found in type 2 diabetes and is currently treated 
with insulin sensitizers (IS). 
 
Aims and Method  
The aim of this literature review was to evaluate whether IS could effectively reduce AD’s 
characteristic pathology and symptoms in models of AD in transgenic mice. The efficacy of an 
IS (Metformin, Rosiglitazone or Pioglitazone) at improving each characteristic in transgenic 
mice was evaluated.  
 
Results 
A variety of cognitive tests and measures of pathology were utilized to assess these outcomes, 
hindering comparison. Improvements in cognition, learning and A pathology were 
demonstrated by some papers, and all papers reported a decrease in tau phosphorylation, 
but no effect on total tau levels. 
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Alzheimer’s Disease (AD) is a debilitating neurodegenerative disorder that contributes to 60-
70% of dementia cases, is rapidly rising in prevalence, yet still has no preventative treatment 
(1).  The characteristic pathology of A aggregation and hyperphosphorylation of tau, found 
upon AD’s discovery in 1907, are still its most identifiable features (2). However, they have 
yet to be linked to one precipitating factor, with the aetiology of this disease still not fully 
understood. Recently, research has been considering impaired insulin signalling as the trigger, 
due to its association with accelerated cognitive decline and neurodegeneration in AD (3–5).  
 
This link between insulin deficiency and resistance and the development of AD pathology has 
led to the proposition that AD may be a neuro-endocrine disorder, and thus could be termed 
‘Type 3 Diabetes’ (T3D) (6). Whilst there is considerable overlap between the physiological 
processes of Type 2 Diabetes (T2D) and AD, the impaired insulin signaling seen in AD is unique 
and brain-specific, so cannot be classed as either Type 1 Diabetes (T1D) or T2D. Potentially 
the strongest evidence in support of T3D is the effect on the cognitive and pathological 
features of AD following the use of insulin sensitizers (IS).  
 
Currently, treatment for AD effects cognitive and non-cognitive symptoms, but are not 
disease modifying (7). A promising new avenue for therapeutic intervention, is to combat the 
impaired insulin signalling found in the brain in AD (8). Peripheral insulin resistance in Type 2 
Diabetes Mellitus (T2D) is prevented by the use of Insulin Sensitizers (IS). The main drugs 
currently used as IS are Metformin (MET) and the Thiazolidinediones (TZD); Rosiglitazone 
(RTZ) and Pioglitazone (PTZ).  
 
Aims 
Consequently, the aim of this study was to evaluate whether, if used in AD, IS may be effective 
at counteracting insulin resistance in the brain and thus repairing insulin signalling (9). This 
would potentially reduce the cognitive decline and characteristic AD pathology shown to be 
a consequence of this pathological process. The effect of IS on A aggregation, 











IS are shown to be effective at reducing the pathology and symptoms of AD in mice, it is 





In order to identify relevant papers, a comprehensive literature search of Ovid Medline, Ovid 
Embase, Pubmed, Scopus and Cochrane library was performed on February 19th 2017. For 
each database, a combination of search criteria was used: Alzheimer’s Disease AND 
Metformin, in addition to Alzheimer’s Disease AND Thiazolidinediones OR Pioglitazone OR 
Rosiglitazone. Relevant papers were then identified by ascertaining their relevance and 
conformity to a set inclusion and exclusion criteria.  
 
Inclusion Criteria: 
 Models of AD in Transgenic mice 




 Effect on cognitive function, Aβ or tau pathology assessed 
 Papers between 2007 and 2017 
 Animal intervention studies 
 
Exclusion Criteria: 
 Human patients with mild to moderate AD or type 2 diabetes 
 Other anti-diabetic drugs or insulin sensitizers used in combination with another 
treatment 
 Effect on mild cognitive impairment or mood dysfunction 













Overall, the databases produced 2101 potentially relevant papers. Only 15 papers ultimately 
met the inclusion criteria for this review (Figure 1).  
 













The 15 papers included in this paper were: 
 
Metformin Papers: 
Barini et al. Metformin promotes tau aggregation and exacerbates abnormal behavior in a  
mouse model of tauopathy. Mol. Neurodegener. 2016; 11, 16. 
DiTacchio et al. Metformin treatment alters memory function in a mouse model of  
Alzheimer’s disease. J. Alzheimer’s Dis. 2015; 44, 43–48. 
Son et al. Metformin Facilitates Amyloid-beta Generation by beta- and gamma-Secretases  
via Autophagy Activation. J. Alzheimers. Dis. 2016; 51, 1197–1208. 
Matthes et al. The anti-diabetic drug metformin improves cognitive impairment and  
reduces amyloid-beta in a mouse model of Alzheimer’s disease. Alzheimer’s Dement.  
2015; 11, P845. 
 
Rosiglitazone Papers: 











neuroinflammation in 3xTg-AD mice. J. Neural Transm. 2015; 122, 593–606. 
O’Reilly and Lynch. Rosiglitazone improves spatial memory and decreases insoluble  
Aβ 1–42 in APP/PS1 mice. J. Neuroimmune Pharmacol. 2009; 7, 140–144. 
Escribano at al. Rosiglitazone reverses memory decline and hippocampal glucocorticoid  
receptor down-regulation in an Alzheimer’s disease mouse model. Biochem. Biophys. 
Res.Commun. 2009; 379, 406–410. 
Escribano et al. (2010). Rosiglitazone rescues memory impairment in Alzheimer’s transgenic  
mice: mechanisms involving a reduced amyloid and tau pathology.  
Neuropsychopharmacology 2010; 35,1593–1604. 
Rodriguez-Rivera et al. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of  
       peripheral gluco-regulatory status. Behav. Brain Res. 2011; 216, 255–261. 
 
Pioglitazone Papers: 
Masciopinto et al. Effects of long-term treatment with pioglitazone on cognition and  
glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis. 2012; 3,  
e448. 
Searcy et al. Long-term pioglitazone treatment improves learning and attenuates  
pathological markers in a mouse model of Alzheimer’s disease. J. Alzheimer’s Dis. 2012;  
30, 943–961. 
Papadopoulos et al. Pioglitazone improves reversal learning and exerts mixed  
cerebrovascular effects in a mouse model of Alzheimer’s Disease with combined amyloid  
β and cerebrovascular pathology. PLoS One 2013; 8, e68612. 
Mandrekar-Colucci et al. Mechanisms underlying the rapid peroxisome proliferator- 
activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a  
murine model of Alzheimer’s disease. J. Neurosci. 2012; 32, 10117–28. 
Nicolakakis et al. Complete rescue of cerebrovascular function in aged Alzheimer’s disease  
transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated  
receptor gamma agonist. J. Neurosci. 2008; 28, 9287–9296. 
Chen et al. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic  












The quality of the remaining 15 papers were assessed for study design, mice characteristics 
and methodology, according to a specific set of criteria (10) (Appendix 1). Each paper was 
then scored according to this criteria (Table 2). These criteria were adapted from the ARRIVE 
guidelines, with the specific scoring for each criteria determined following further research 
and discussion.  
 
A wide variety of genotypes were used in these papers, to produce models of AD in transgenic 
mice. As shown in Figure 2, each model develops different pathological features of AD at 
varying ages. 3xTg AD mice were found to be the most accurate representation of AD and 
thus scored 5 points. It is the sole model to incorporate 3 known AD specific genes, and 
develop both SPs and NFTs (11). The remaining models used single or double transgenic 
models that only demonstrated 1 of the pathological features of interest and thus scored 
poorly.  
 
Figure 2. A visual model of AD pathology in certain models of AD in mice 
 
A visual model comparing the different ages of onset (in months) of key pathology and 













APPswe/PSEN1dE9 are available. Whilst Mandrekar-Colucci et al. and  O’Reilly and Lynch state 
that model 1 is used, Chen et al. and Matthes et al. do not clearly indicate which model was 
utilized, so may have used either. 
This model was created on ALZFORUM’s site and can be accessed at: 
(http://www.alzforum.org/research-models/alzheimers-disease) 
mo – months old, yr – year. 
 
The age and genotype of the mice used are closely interlinked, with the extent of the 
pathology differing depending on these 2 factors. Consequently, the age of the mice can 
considerably effect the outcomes. Excluding APPswe/PS1dE9’s delayed development of 
cognitive impairment (+12 months), the average age of onset (AAO) of cognitive decline was 
4.67 months. Likewise, the average AAO for A pathology was 5.83 months and tau was either 
at 5 or 12 months. Some studies introduced the drug at a far later age, potentially once the 
degree of pathology was too extensive for the drugs to effectively make any impact, and thus 
were scored poorly. Likewise, by starting the treatment before the average AAO of these 
pathological and cognitive features, experiments explored the potential for IS to be used as a 
preventative treatment rather than a cure, so received an equally low score. 
 
The average duration of treatment was approximately 5 months. The longer the duration of 
the treatment, the more reliable the results, as this gave the drug more time to produce its 
effects. Thus, studies that administered the drug for more than 4 months, considerably 
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Each study characteristic was scored out of 5, with a maximum score of 60 possible for 
exceptional studies. The strongest studies and characteristics are green and the weakest are 













Four out of five RTZ papers showed improved cognition and they all demonstrated 
improved Aβ pathology (Figure 3). In PTZ studies assessing both learning and memory, only 
learning was shown to improve. However, out of the four studies assessing purely memory, 
three identified some improvements in this area. Whilst two papers reported an 
improvement in Aβ pathology, two reported no effect. Only two MET papers evaluated 
cognition. Whilst one paper reported improved learning, the other only reported improved 
memory in females, with increased memory impairment seen in males. One paper reported 
an increase in Aβ pathology and another a decrease. All three drugs reported a decrease in 
tau phosphorylation, but no effect on total tau levels.  
 
Figure 3. Graphs showing the results of the cognitive and pathology tests  
 
Only 2 studies used more than one cognitive test and 2 papers used no cognitive tests at all. 8 
papers measured A levels and only 4 papers investigated tau pathology.  
MWM – Morris Water Maze, ORT – Object Recognition 
 
Discussion 
This paper aims to critically assess whether IS are effective at reducing the characteristic 
cognitive impairment and pathology seen in AD, by looking at models of AD in transgenic 
mice. Whilst the majority of the results present an aspect of cognitive improvement, the 
findings are heterogeneous, reducing confidence in the outcomes produced. Fewer papers 















RTZ was found to be effective at improving cognition, Aβ pathology and tau phosphorylation, 
suggesting it is the most effective IS. Although the majority of the evidence supports this 
conclusion, it should be treated with caution, as systematic errors in the methodology 
resulted in poor internal validity and reliability.  
 
Pioglitazone 
PTZ had the highest internal validity, incorporating elements of randomization and blinding 
that were notably absent from the other drugs. However, flaws in the study design produced 
substantial heterogeneity within the results. PTZ has been shown to be effective at decreasing 
tau phosphorylation and improving learning, more than memory, in mice. Whilst the evidence 
in support of PTZ’s ability to improve Aβ pathology is more reliable than the evidence against 
it, the results are still inconclusive, with the overall reliability of the data weak in support of 
either argument.  
 
Metformin 
The low quality of the study designs in every MET paper made it impossible to draw any 
definitive conclusions on its efficacy. Although it is found to be similarly effective at reducing 
tau phosphorylation, the reliability of the data on cognition and Aβ pathology is poor, 
hindering any conclusive outcomes from being determined. 
 
Study quality 
The heterogeneous nature of the results can be contributed to the numerous confounders 
and poor study design of the papers analyzed. A variety of cognitive tests and measures of 
pathology were utilized to assess these outcomes, hindering comparison. Similarly, mice 
characteristics varied hugely between papers. The papers exhibited numerous forms of bias, 
reducing the internal validity and impacting the reliability of the outcomes. Instances of 











analyzed. This low internal validity is highlighted in Table 2, with insufficient blinding and a 
lack of randomization particularly prevalent. This increases bias and thus reduces the 
reliability of the results. Additionally, the use of mice significantly reduces the external validity 
of these studies as the ability to extrapolate these results into humans is limited by the 
biological differences between the two. 
 
Current context 
Previous studies investigating the use of TZD to improve cognition in mild-to-moderate AD 
patients have produced conflicting results. Early phase II (12) and phase III (13) double-blind, 
randomized, placebo-controlled trials showed improved cognition upon RTZ treatment. 
However, more recent phase III clinical trials (14,15) have found no effect of RTZ treatment 
on cognition. Similarly, smaller clinical trials for PTZ disagree on the efficacy of this drug in 
mild-to moderate AD patients. 2 pilot clinical trials showed improved memory and cognition 
in patients with mild AD and T2D (16,17), whereas no benefit was found in a similar study 
which used patients with AD but not T2D (18). This suggests that PTZ may only have an effect 
in patients with diabetes. There are currently no clinical trials on the use of MET in patients 
with AD. In order for IS to be successful in humans, how they exert their effects on mice has 
to be determined. The differing efficacy between TZD and MET suggest it can’t be purely due 
to their effects on glucose regulation. Therefore, by determining what element in their 
mechanism of action improves cognition and pathology, treatment can target this factor and 
potentially be used more effectively in humans. 
 
Conclusion 
Initially the results from these studies appeared too heterogeneous to conclusively 
determine any effect by IS. However, analysis of the accuracy and reliability of the studies 
highlighted outcomes that supported the IS’s, in particular the TZD’s, ability to improve the 
symptoms and pathology of AD in mice. However, the level of confidence in these conclusions 
is significantly impacted by consistent flaws in the study design. In order to confidently 
conclude that IS are effective, more studies of greater internal validity are required. The 
disparity in the efficacy of each drug, suggests that it is not purely the insulin sensitizing 











in TZD at improving the symptoms and pathology of AD in mice, studies of a greater quality, 
accuracy and internal validity are needed to learn more about how IS exert their effect, before 
they can be effectively used in humans. 
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